An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma

Assessing response to therapy in lymphoma is important for determining patients ’ prognosis, guiding subsequent treatment, and may be used as an outcome measure of prognostic and therapeutic trials. Traditionally, computed tomography was the mainstay for response assessment and was predominantly performed at the end of treatment, whereas the most recent guidelines propose 18F -fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) for this purpose. However, the value of FDG-PET performed during treatment (interim FDG-PET) is still a topic of debate.

Source: Seminars in Oncology - February 2, 2018 Category: Cancer & Oncology Authors: Hugo J.A. Adams, Thomas C. Kwee Source Type: research